{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:12:21Z","timestamp":1707523941663},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,19]]},"DOI":"10.7759\/cureus.45532","type":"journal-article","created":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T11:40:16Z","timestamp":1695123616000},"source":"Crossref","is-referenced-by-count":0,"title":["A Five-Year Retrospective Audit on Bone Protection Prescribing in Patients With Fragility Fractures in Primary Care"],"prefix":"10.7759","author":[{"given":"Ishtar A","family":"Redman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicnesan","family":"Sivanesan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-021-04051-9","article-title":"Fragility fracture identifies patients at imminent risk for subsequent fracture: real-world retrospective database study in Ontario, Canada","volume":"22","author":"Adachi JD","year":"2021","unstructured":"Adachi JD, Brown JP, Schemitsch E, et al.. Fragility fracture identifies patients at imminent risk for subsequent fracture: real-world retrospective database study in Ontario, Canada. BMC Musculoskelet Disord. 2021, 22:224. 10.1186\/s12891-021-04051-9","journal-title":"BMC Musculoskelet Disord"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-022-06647-w","article-title":"A 3-year retrospective analysis of patients admitted with clinical vertebral fragility fractures across hospitals in England, UK","volume":"34","author":"Tan CW","year":"2023","unstructured":"Tan CW, Sahota O. A 3-year retrospective analysis of patients admitted with clinical vertebral fragility fractures across hospitals in England, UK. Osteoporos Int. 2023, 34:607-11. 10.1007\/s00198-022-06647-w","journal-title":"Osteoporos Int"},{"key":"ref3","unstructured":"NICE. Bisphosphonates for treating osteoporosis; technology appraisal guidance [TA464]. (2019). Accessed. August 01, 2023: https:\/\/www.nice.org.uk\/guidance\/ta464."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-015-3277-9","article-title":"Impact of hip fracture on hospital care costs: a population-based study","volume":"27","author":"Leal J","year":"2016","unstructured":"Leal J, Gray AM, Prieto-Alhambra D, Arden NK, Cooper C, Javaid MK, Judge A. Impact of hip fracture on hospital care costs: a population-based study. Osteoporos Int. 2016, 27:549-58. 10.1007\/s00198-015-3277-9","journal-title":"Osteoporos Int"},{"key":"ref5","unstructured":"Royal College of Physicians warns the UK is facing a crisis in care for older people. (2022). Accessed. August 01, 2023: https:\/\/www.rcplondon.ac.uk\/news\/rcp-warns-uk-facing-crisis-care-older-people#:~:text=The%20RCP%20is%20warning%20that...."},{"key":"ref6","unstructured":"ONS. Overview of the UK population. 2020\r\n. (2020). Accessed: August 01, 2023: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/populationandmigration\/populationestimates\/articles\/overviewofthe...."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.5152\/eurjrheum.2016.048","article-title":"An overview and management of osteoporosis","volume":"4","author":"S\u00f6zen T","year":"2017","unstructured":"S\u00f6zen T, \u00d6z\u0131\u015f\u0131k L, Ba\u015faran N\u00c7. An overview and management of osteoporosis. Eur J Rheumatol. 2017, 4:46-56. 10.5152\/eurjrheum.2016.048","journal-title":"Eur J Rheumatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-019-04852-8","article-title":"Risk of imminent fracture following a previous fracture in a Swedish database study","volume":"30","author":"Banefelt J","year":"2019","unstructured":"Banefelt J, \u00c5kesson KE, Sp\u00e5ng\u00e9us A, et al.. Risk of imminent fracture following a previous fracture in a Swedish database study. Osteoporos Int. 2019, 30:601-9. 10.1007\/s00198-019-04852-8","journal-title":"Osteoporos Int"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black DM","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB, et al.. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996, 348:1535-41. 10.1016\/s0140-6736(96)07088-2","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e328335729c","article-title":"Bisphosphonates pathway","volume":"21","author":"Gong L","year":"2011","unstructured":"Gong L, Altman RB, Klein TE. Bisphosphonates pathway. Pharmacogenet Genomics. 2011, 21:50-3. 10.1097\/FPC.0b013e328335729c","journal-title":"Pharmacogenet Genomics"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-010-9364-1","article-title":"Adverse effects of bisphosphonates","volume":"86","author":"Abrahamsen B","year":"2010","unstructured":"Abrahamsen B. Adverse effects of bisphosphonates. Calcif Tissue Int. 2010, 86:421-35. 10.1007\/s00223-010-9364-1","journal-title":"Calcif Tissue Int"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2165\/00024677-200201010-00004","article-title":"Gastrointestinal adverse effects of bisphosphonates: etiology, incidence and prevention","volume":"1","author":"Lanza FL","year":"2002","unstructured":"Lanza FL. Gastrointestinal adverse effects of bisphosphonates: etiology, incidence and prevention. Treat Endocrinol. 2002, 1:37-43. 10.2165\/00024677-200201010-00004","journal-title":"Treat Endocrinol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.2007.057505","article-title":"The role of DXA bone density scans in the diagnosis and treatment of osteoporosis","volume":"83","author":"Blake GM","year":"2007","unstructured":"Blake GM, Fogelman I. The role of DXA bone density scans in the diagnosis and treatment of osteoporosis. Postgrad Med J. 2007, 83:509-17. 10.1136\/pgmj.2007.057505","journal-title":"Postgrad Med J"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3194","article-title":"The ability of a single BMD and fracture history assessment to predict fracture over 25 years in postmenopausal women: the study of osteoporotic fractures","volume":"33","author":"Black DM","year":"2018","unstructured":"Black DM, Cauley JA, Wagman R, et al.. The ability of a single BMD and fracture history assessment to predict fracture over 25 years in postmenopausal women: the study of osteoporotic fractures. J Bone Miner Res. 2018, 33:389-95. 10.1002\/jbmr.3194","journal-title":"J Bone Miner Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s11914-021-00660-4","article-title":"Bisphosphonate drug holidays in primary care: when and what to do next?","volume":"19","author":"Bauer DC","year":"2021","unstructured":"Bauer DC, Abrahamsen B. Bisphosphonate drug holidays in primary care: when and what to do next?. Curr Osteoporos Rep. 2021, 19:182-8. 10.1007\/s11914-021-00660-4","journal-title":"Curr Osteoporos Rep"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2015.1000860","article-title":"Denosumab for the treatment of osteoporosis","volume":"11","author":"Zaheer S","year":"2015","unstructured":"Zaheer S, LeBoff M, Lewiecki EM. Denosumab for the treatment of osteoporosis. Expert Opin Drug Metab Toxicol. 2015, 11:461-70. 10.1517\/17425255.2015.1000860","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12022","article-title":"Denosumab: mechanism of action and clinical outcomes","volume":"66","author":"Hanley DA","year":"2012","unstructured":"Hanley DA, Adachi JD, Bell A, Brown V. Denosumab: mechanism of action and clinical outcomes. Int J Clin Pract. 2012, 66:1139-46. 10.1111\/ijcp.12022","journal-title":"Int J Clin Pract"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/189425-a-five-year-retrospective-audit-on-bone-protection-prescribing-in-patients-with-fragility-fractures-in-primary-care","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:53:19Z","timestamp":1707508399000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/189425-a-five-year-retrospective-audit-on-bone-protection-prescribing-in-patients-with-fragility-fractures-in-primary-care"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,19]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.45532","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,19]]}}}